Multi-peptide CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Bone Marrow Transplantation Recipient;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma Interventions:   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Laboratory Biomarker Analysis;   Other: Placebo Sponsor:   City of Hope Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials